Welcome to our dedicated page for BIOINVENT INTL NEW news (Ticker: BOVNF), a resource for investors and traders seeking the latest updates and insights on BIOINVENT INTL NEW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BIOINVENT INTL NEW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BIOINVENT INTL NEW's position in the market.
On April 29, 2021, BioInvent International AB held its Annual General Meeting (AGM) in Lund, Sweden. The AGM resulted in the election of Vincent Ossipow as a new Board member and the re-election of existing members including Kristoffer Bissessar and Leonard Kruimer as Chairman. The income statements and balance sheets for 2020 were approved, with no dividend declared. The Board's fee was set at SEK 682,500 for the Chairman and SEK 325,000 for other members. The Board was authorized to issue new shares, which could not exceed a 20% dilution effect on share capital. The full minutes are available on the company's website.
BioInvent International AB announced that its partner, Oncurious NV, presented Phase I data on TB-403 for pediatric medulloblastoma at the AACR annual meeting. The findings support further evaluation of TB-403, which has Orphan Designation from EMA. BioInvent previously co-developed TB-403, but it is no longer a focus project, and the company retains 50% of future revenues post-development costs. BioInvent specializes in novel cancer therapies and has three drug candidates in clinical trials.
BioInvent International AB published its Annual Report for 2020, showcasing its commitment to developing innovative cancer therapies. The company operates three drug candidates in clinical trials, leveraging its proprietary F.I.R.S.T™ technology. This platform allows for the simultaneous identification of therapeutic targets and antibodies. BioInvent also generates revenue through collaborations and antibody production for third parties. The report is accessible on their website for stakeholders seeking detailed insights into the company’s performance and strategic direction.
BioInvent International AB announces an increase in its total shares to 58,471,096 as of March 31, 2021, following a directed issue that raised MSEK 819. This issuance involved 16,260,601 shares sold to institutional investors, approved by the General Meeting on March 23, 2021. BioInvent focuses on developing first-in-class immuno-modulatory antibodies for cancer therapy, with three candidates in clinical trials. Revenue is generated through research collaborations and license agreements with top pharmaceutical firms.
BioInvent International AB announced the publication of proof-of-concept data for its fully human FcγRIIB-blocking antibody, BI-1607, at the AACR Annual Meeting 2021. This novel antibody enhances anti-cancer immunity and aims to improve outcomes against resistant cancers. CEO Martin Welschof stated the company plans to submit a clinical trial application for BI-1607 in H2 2021, marking it as their fourth drug candidate in clinical development. BioInvent also has ongoing trials for its other drug candidates, enhancing its clinical portfolio.
BioInvent and Transgene announced the enrollment of the first patient in a Phase I/IIa trial for the oncolytic virus BT-001, designed for cancer treatment. This dual mechanism of action virus targets the tumor microenvironment and combines a Treg-depleting anti-CTLA-4 antibody and GM-CSF cytokine. The trial's first part will include up to 36 patients with advanced solid tumors, while the second part will explore combinations with pembrolizumab. This effort enhances BioInvent's clinical pipeline, now featuring three candidate products and four studies.
BioInvent has begun 2021 with strong momentum, showcasing interim efficacy data from its Phase I/IIa trial of BI-1206. The company secured a successful financing round of SEK 962 million, broadening its institutional shareholder base. Additionally, BioInvent expanded its clinical pipeline to include two more drug candidates targeting solid tumors. Key financial indicators for 2020 showed net sales increased to SEK 147.4 million, while losses decreased to SEK -76.3 million. Significant partnerships and milestones were achieved, enhancing BioInvent's growth and strategic position.
BioInvent International AB (OMXS: BINV) will release its interim report for Q2 2020 on August 27 at 8:00 a.m. CEST. This will be followed by an audiocast and teleconference at 5:30 p.m. CEST, led by CEO Martin Welschof and the management team. Participants can join via phone or webcast. BioInvent is focused on developing immuno-modulatory antibodies for cancer treatments, with ongoing clinical programs and a proprietary technology platform. Further details are available on their website.
FAQ
What is the market cap of BIOINVENT INTL NEW (BOVNF)?
